Related Experiment Videos
VLA-2 is a collagen receptor on endothelial cells
P J O'Connell1, R Faull, G R Russ
1Department of Nephrology, Royal Melbourne Hospital, Victoria, Australia.
Immunology and Cell Biology
|April 1, 1991
Summary
Researchers identified a novel antibody, RMAC11, that targets the very late antigen-2 (VLA-2) receptor on human umbilical vein endothelial cells. This antibody blocks endothelial cell adhesion to collagen and laminin, confirming VLA-2
Area of Science:
- Cell Biology
- Immunology
- Biochemistry
Background:
- Vascular endothelium plays a critical role in cell-substrate adhesion.
- Identifying specific adhesion receptors is crucial for understanding endothelial cell function.
- Murine monoclonal antibodies (MoAb) were generated against human umbilical vein endothelial cells (HUVE) to identify these receptors.
Purpose of the Study:
- To identify cell-substrate adhesion receptors on vascular endothelium.
- To characterize the function of the very late antigen-2 (VLA-2) receptor.
- To investigate the role of VLA-2 in HUVE adhesion to extracellular matrix proteins.
Main Methods:
- Generation of murine monoclonal antibodies against HUVE.
- Immunoprecipitation assays using anti-VLA-2 and anti-HUVE antibodies.
- Proteolytic peptide mapping to compare protein structures.
- In vitro adhesion assays of HUVE to collagen, laminin, and fibronectin.
Main Results:
- One monoclonal antibody, RMAC11, identified VLA-2 by immunoprecipitating a 160 kD and 130 kD heterodimer.
- Proteolytic peptide maps confirmed the homology between RMAC11-recognized molecule and VLA-2.
- RMAC11 also identified an 85 kD band, potentially a VLA-2 alpha-chain fragment or associated molecule.
- RMAC11 blocked HUVE adhesion to collagen (types 1 and 4) and laminin, but not fibronectin.
Conclusions:
- VLA-2 is confirmed as a collagen and laminin receptor for HUVE.
- The monoclonal antibody RMAC11 is a valuable tool for studying VLA-2 function.
- RMAC11 may recognize a novel molecule associated with VLA-2 or a specific VLA-2 fragment.